My research efforts since qualification have focussed largely in the HIV research arena over a period of 27 years.

This can be supported by numerous peer reviewed publications and conference presentations. I believe I have contributed significantly to the development of capacity for affordable, accessible HIV and TB diagnosis and monitoring in South Africa and over 60 centres in sub-Saharan Africa. Research activities have included the expansion of early infant diagnosis of HIV, affordable HIV viral load, CD4 and investigation of HIV drug resistance.

In 2006, I received an award from the National Department of Science and Technology for my contribution to the development of laboratory capacity in Southern

Africa. I have been an advisor to and an investigator for the following HIV research networks: the International AIDS Vaccine Initiative (IAVI) (New York), the HIV Vaccine Trials Network (HVTN) (NIH funded, SeaUle), the AIDS Clinical Trials Group (ACTG) (NIH funded), the Microbicide Development Program (UK based funding) and the ACTG Pharmacology Scientific CommiUee, amongst others. In addition, I have had investigator status for several international grants funded projects including the CIPRA (NIH: IU19 A15ti217-01) project in collaboration with Professor McIntyre and team at the University of the Witwatersrand (Wits). Other funders of my research have more recently included: the Netherlands AIDS fund, Gates Foundation, Grand Challenges Canada Global Fund, PEPFAR, CDC, USAID, and the MRC. I have served as a consultant for the World Health Organization (Geneva), CDC (Atlanta) and NIH (Bethesda, USA) on several different working groups. I also serve on review committees for UNITAID (WHO), Bill and Melinda Gates Foundation Grand Challenges. Since November 2010, I have undertaken a role and have been appointed Head of National Priority Programs at the National Health Laboratory Service focusing on laboratory efforts related to priority diseases that currently HIV, TB and Cervical Cancer. My current portfolio includes options for implementation at scale through the National Priority Programme and optimising the clinic laboratory chain through innovations for Africa by means of the African Innovation Network (www.ileadinnovation.africa). During the more recent SARs-CoV-2 outbreak, my team was responsible for National assay validation; molecular, serology and antigen/antibody-based testing. As the Divisional Executive Director and founder of the newly established Wits Diagnostic Innovation Hub (Wits DIH) at the University of the Witwatersrand, my team and I aim to accelerate Africa's access to affordable innovative diagnostic technologies, but providing a platform for innovators and suppliers to evaluate and validate these technologies, as well as provide guidance to regulatory and implementation frameworks within a real-world setting